| created | [InstanceEdit:9726503] Jassal, Bijay, 2021-04-07 |
| dbId | 9726517 |
| displayName | Fludrocortisone is a synthetic mineralocorticoid used in con... |
| literatureReference |
|
| modified | [InstanceEdit:9726525] Jassal, Bijay, 2021-04-07 |
| schemaClass | Summation |
| text |
Fludrocortisone is a synthetic mineralocorticoid used in conjunction with hydrocortisone to replace missing endogenous corticosteroids in patients with adrenal insufficiency. It is functionally similar to aldosterone, the body's primary endogenous mineralocorticoid, and is structurally analogous to cortisol, differing only by a fluorine atom at the 9-position of the steroid structure and having similar affinity for the mineralocorticoid receptor (NR3C2) as aldosterone (Rupprecht et al. 1993, Oelkers et al. 1994). Fludrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing androgenital syndrome (Charmandari et al. 2014, Hamitouche et al. 2017). Fludrocortisone has also shown to be effective in the treatment of cerebral salt-wasting syndrome (Taplin et al. 2006, Misra et al. 2018). Common side effects of fludrocortisone include high blood pressure, swelling, heart failure, and low blood potassium. |
| (summation) |
© 2026 Reactome